To investigate this potential cooperativity, we analyzed bulk RNAseq data from 71 patients from our earlier clinical study of combined BRAF/EGFRi ± MEKi in patients with BRAFV600E CRC, including 45 paired patient biopsies (pretreatment and day 15 on treatment) and 26 separate biopsies from baseline25. This evidence concerns the gene BRAF and colorectal carcinoma.